Tag: risk

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

Vancouver, BC, June 24, 2025 (GLOBE NEWSWIRE) -- Oxley Bridge Acquisition Limited (the “Company”) announced today the pricing of its initial public offering of 22,000,000 units at a price of $10.00 per unit. The units are expected to be listed on The Nasdaq Global Stock Market LLC (“Nasdaq”) and begin trading on June 25, 2025, under the ticker symbol “OBAWU.” Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, each whole warrant entitling the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. An amount equal to $10.00 per unit will be deposited into a trust account upon the closing of the offering. Once the securities constituting the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on Nasdaq under the symbols “OBA” and “OBAWW,” respectively. The offering is expected to close on June 26, 2025, subject to customary closing conditions. The Company has granted the underwriters a 45-day option to purchase up to an additional 3,300,000 units at the initial public offering price to cover over-allotments, if any.

Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held

Following the reverse share split, the Company will have approximately 534,600 outstanding shares, out of which approximately 516,727 will be publicly held

TORONTO, June 24, 2025 /CNW/ - Andlauer Healthcare Group Inc. (TSX: AND) ("AHG" or the "Company") today announced that at its special meeting of...

CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2

CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2

CALGARY, AB, June 24, 2025 /CNW/ - Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) held its annual and special meeting of...

CALGARY, AB, June 24, 2025 /PRNewswire/ - Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) held its annual and special meeting of...

CALGARY, AB, June 24, 2025 /PRNewswire-HISPANIC PR WIRE/ -- Parkland Corporation ("Parkland", "we", the "Company", or "our") (TSX: PKI) held its annual and special...

WASHINGTON, June 24, 2025 /PRNewswire/ -- Today, on the third anniversary of the U.S. Supreme Court decision in Dobbs v. Jackson Women's Health Organization, Family...

A new high–grade sub-zone ("HZ2"), enriched in copper and silver, has been discovered in the Apollo system. HZ2, which remains open for expansion, is...